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N e w s & V I e w s
In order to understand the complex interplay between infiltrating immune cells and disease-altered stromal cells in inflamed synovium, future studies will need to build on these pioneering studies in many areas (Fig. 1) . Although the studies by Orange et al. and Stephenson et al. understandably focused on synovial tissue obtained during joint replacement surgery, such tissue samples are unrepresentative of RA pathology, particularly the clinically important early stages of the disease. Performing synovial biopsies in treatmentnaive patients will be crucial for distinguishing inflammation in reaction to ongoing joint damage from inflammatory mechanisms driving disease processes. Biopsies performed before treatment with steroids, DMARDs or biologics might reveal stronger signals that can differentiate true disease endotypes, just as biopsies for classifying lymphoma are best performed before steroid treatment 8 .
In terms of measuring disease activity, obtaining accurate clinical data that incorporate ultrasound and radiographic imaging will enable a more objective estimation of disease burden compared with disease activity measures that rely on subjective patient measures such as pain scores and tender joint count. The integration of data from multiple omics platforms into measurements of disease activity will provide increased depth of knowledge of the disease process in RA. However, with the massive expansion in data, more refined, standardized, machine learning algorithms that are suited to heterogeneous, high-dimensional and statistically noisy data sets will be required. The lack of consensus surrounding the best approaches for analysing data remains a barrier. Furthermore, true validation of biomarkers identified by multiomics studies will require carefully collected replication cohorts as standard practice.
1.
Nam 
Competing interests
The authors declare no competing interests. . High-dose (1-2 g/kg) IVIG, a pooled normal IgG preparation, remains a lifesaving therapeutic option for numerous autoimmune and inflammatory diseases 2, 3 . The efficacy of this immunotherapy in diseases with distinct immunopathogenic mechanisms suggests that the therapeutic benefits of IVIG are mediated through diverse mechanisms, a notion confirmed by experimental and clinical reports 2, 3 .
The effects of IVIG can depend on the F(ab) 2 portion or the Fc fragment of the IgG molecule, or might require the entire molecule. One of the earliest mechanisms of IVIG to be described was the blockade of FcγRs, which was attributed solely to the Fc fragment of IgG. Hence, the use of the Fc fragment has been proposed as an alternative to IVIG therapy in immune complex-driven diseases. In fact, the Fc fragment was efficacious in treating children with acute immune thrombocytopenic purpura (ITP) in a clinical trial 4 . Despite these promising results, however, the expansion of FcγR-targeted therapeutics for the autoimmune and inflammatory diseases has been slow, mainly owing to incomplete knowledge of the functioning and diversity of Fc receptors, the molecular pathogenesis of these pathologies and protein engineering being in its infancy.
In the past decade, the development of Fc-based therapeutics, in particular, multimerized polyvalent forms, has gained momentum. The observation that human IgG2 in the serum can form hinge region-dependent dimers led to the design of fully recombinant IgG2a Fc multimers called stradomers; these stradomers demonstrated therapeutic efficacy in several models of autoimmune diseases, including collagen-induced arthritis (CIA), ITP and myasthenia gravis 5, 6 . Multivalent . Altogether, the results reported by Spirig et al. 1 could reinforce and propel the development of Fc-based therapeutics for auto immune and inflammatory diseases. Although the Fc hexamers showed therapeutic effects in acute models of autoimmune diseases, the short half-life of this multimer and its limited mechanism of action (compared with IVIG) are major drawbacks. Also, whether Fc-based therapeutics would be beneficial in auto immune diseases in which T cells are the major mediators of pathogenic responses remains to be determined. As with any recombinant protein, the immunogenicity of the hexamer following repeated therapy, and the role of glycans in its anti-inflammatory actions and binding properties, also need to be addressed. Alternatively, high-avidity binding properties of Fc hexamers and their inhibitory effects on classical and lectin pathways of complement activation could be exploited in the form of combination therapy with IVIG. Whereas Fc hexamers exert rapid suppressive effects on inflammation, the multi-pronged action of IVIG ensures durable therapeutic effects.
Emmanuel Stephen-Victor 1 , although these molecules were not tested for the therapy of autoimmune diseases and complement activation under physiological conditions. Together, these reports suggested that FcγR-mediated activation signals in autoimmune diseases could be blocked by using multimers of Fc domains.
Building on the aforementioned work, Spirig et al. 1 now report that a recombinant IgG1 Fc hexamer, termed Fc-μTP-L309C, potently inhibits FcγR-mediated activation signals and alleviates acute and chronic autoimmune diseases in mice. The recombinant hexamer was developed by fusing the μ-tailpiece from human IgM with the carboxy terminus of human IgG1. Furthermore, a point mutation at position 309 from leucine to cysteine was introduced that imparted stability to the hexamer by forming additional covalent bonds. Fc-μTP-L309C, but not the Fc monomer, avidly bound to low-affinity FcγRs such as CD16a, CD32a and CD32b/c as well as to the high-affinity receptor CD64 (REF.
1
). In addition, Fc-μTP-L309C had greater avidity than IVIG for neonatal FcR (FcRn), a receptor implicated in prolonging the half-life of antibodies (Fig. 1) . Functional assessments demonstrated that the hexamer inhibited antibody-dependent cell-mediated cytotoxicity and phagocytosis -crucial effector responses triggered by immune complexes upon binding to FcγRs. Of note, these effects of Fc-μTP-L309C were not associated with undesirable activation of immune cells.
Having established that Fc-μTP-L309C could inhibit FcγR-mediated functions in vitro, Spirig et al. 1 next evaluated the efficacy of the hexamer in vivo in an antibodymediated model of acute arthritis. Treatment with a single dose of Fc-μTP-L309C (200 mg/kg; a dose 10-fold lower than that of IVIG) markedly decreased the formation of complement proteins C3 and C5a in the knee joints and also ameliorated bone degradation, restricted inflammatory cell infiltration and inhibited an array of pro-inflammatory cytokines and chemokines. The therapeutic effect of Fc-μTP-L309C was rapid (as early as 24 h after administration) and was sustained for up to 14 days. By contrast, IVIG had minimal effects even at day 8 and a clear therapeutic efficacy was observed only by day 14, reflecting the delayed kinetics of the response to IVIG in comparison with Fc-μTP-L309C. In a model of ITP, a single dose (200 mg/kg) of Fc-μTP-L309C sharply increased the platelet counts to levels comparable to those achieved by treatment with IVIG 1 . Similar protective effects of Fc-μTP-L309C in a rat model of neuromyelitis optica have also been reported by another group 9 . The rapid therapeutic effects of Fc-μTP-L309C in acute models of auto immune diseases is not surprising as hexamers of IgG1 bind to FcγRs with higher avidity than the monomeric IgG in IVIG. Because of this binding, Fc-μTP-L309C inhibits pathogenic antibody-mediated inflammatory processes.
In a model of chronic arthritis, although Fc-μTP-L309C improved the clinical signs of CIA its effect waned over time and additional doses were required; by contrast, such additional therapy was not required for IVIG-treated mice 1 . Two main factors could explain these observations. First, the half-life of Fc-μTP-L309C is 3.1 hours in mice (for comparison, IgG molecules have a half-life of nearly 7 days in mice and approximately 21 days in humans) so although an initial infusion of Fc-μTP-L309C would block immune complex-mediated activation of immune cells, sustained production of pathogenic antibodies and concomitant clearance of infused Fc-μTP-L309C would lead to flares of disease. Second, unlike Fc-μTP-L309C, the mechanism of action of IVIG is not dependent solely on FcγR blockade and inhibition of 
